The comparison of median, mean, first, and third quartile concentration of (a) total Thiol, (b) NO, (c) MDA, <i>and</i> (d) FRAP in GST, GT, and PT. by Alireza Bastin (12359849)

Subjects:

Non-metric Multidimensional Scaling (NMDS) plot showing significant correlations (<i>P</i> < 0.05) between microbiota and clinical variables in the Staph group. by Paulo Kussek (13410476)

Column charts of SI_8min and SI_10min in the therapy and control group at follow-up. by Felix L. Herr (21544362)

Subjects:

Column charts of WiAUC in therapy and control group at baseline and follow-up. by Felix L. Herr (21544362)

Subjects:

Image_1_Decrease in Serum Urate Level Is Associated With Loss of Visceral Fat in Male Gout Patients.tif by Zijing Ran (11429935)

“…By multiple regression model, ΔSU was identified to be a significant determinant variable of decrease in VFA (beta, 0.302; p = 0.001).…”

Clinical relapse rate after colonoscopy. by Yuriko Otake-Kasamoto (15314630)

Subjects:

Changes in vital signs after colonoscopy. by Yuriko Otake-Kasamoto (15314630)

Subjects:

Subjective symptoms after colonoscopy. by Yuriko Otake-Kasamoto (15314630)

Subjects:

Procedural characteristics. by Yuriko Otake-Kasamoto (15314630)

Subjects:

Bar graphs showing the clinical relapse rate that was analyzed separately by the Mayo endoscopic subscore. by Yuriko Otake-Kasamoto (15314630)

Subjects:

Flow diagram of the study. by Yuriko Otake-Kasamoto (15314630)

Subjects:

Clinical relapse rate after colonoscopy adjusted by Mayo endoscopic subscore (MES) or partial Mayo score (PMS). by Yuriko Otake-Kasamoto (15314630)

Subjects:

Characteristics of the participants in the study. by Yuriko Otake-Kasamoto (15314630)

Subjects:

Summary of PaO₂, lactic and blood glucose with repeated measurement (mean, 95% CI). by Guangquan An (11473126)

Subjects:

The forest plots of pooled estimates of standardized mean differences of circulating apelin (A), apelin/HDL-c (B), apelin/LDL-c (C), apelin/triglycerides (D), and apelin/total chol... by Hamed Akbari (8119361)

Subjects:

Changes in the liver fibrosis-related markers in breast cancer patients with a FIB-4 index of >2.30 during letrozole treatment. by Kazuyoshi Ohkawa (836847)

Subjects:

Flowchart of patient selection in this study. by Kazuyoshi Ohkawa (836847)

Subjects:

Changes in the FIB-4 index in breast cancer patients with a FIB-4 index of ≥ 2.67 during letrozole and anastrozole treatment. by Kazuyoshi Ohkawa (836847)

Subjects:

Changes in the liver fibrosis-related markers in breast cancer patients with a FIB-4 index of >2.30 during anastrozole treatment. by Kazuyoshi Ohkawa (836847)

Subjects:

Clinical features and cancer treatment in patients with breast cancer receiving letrozole and anastrozole. by Kazuyoshi Ohkawa (836847)

Subjects: